[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | 1266239-90-0

• 英文名称: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
• CAS: 1266239-90-0
• 化学式: C53H57N7O16
• 分子量: 1048.1
• InChiKey: KQZLMNNWZDXAHG-NOSCCTPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  76
• 可旋转键数：
  15
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  327
• 氢给体数：
  5
• 氢受体数：
  19

文献信息

• SELF-SEALING CATHETERS
  申请人：Walkill Concepts, Inc.

  公开号：EP2793990A1

  公开（公告）日：2014-10-29
• [EN] SELF-SEALING CATHETERS<br/>[FR] CATHÉTERS AUTO-OBTURANTS
  申请人：WALKILL CONCEPTS INC

  公开号：WO2013096463A1

  公开（公告）日：2013-06-27

  Provided are catheters useful for penetrating the vascular wall and delivering medicament as necessary to tissue proximate the vasculature. Such catheters are particularly useful in delivering site specific medicaments to the tissue which can be damaged by hemorrhagic stroke, ischemia, and the like. Methods of using such catheters are also disclosed.
• [EN] TREATING SOLID TUMOURS WITH NK-92 CELLS APPLIED BY MICROCATHETER<br/>[FR] TRAITEMENT DE TUMEURS SOLIDES PAR DES CELLULES NK-92 APPLIQUÉES PAR MICROCATHÉTER
  申请人：CONKWEST INC

  公开号：WO2015179710A1

  公开（公告）日：2015-11-26

  Disclosed herein are methods for treating solid mass tumors with direct delivery of an anti-tumor immunotherapeutic agent to the tumor site. In one aspect, this invention encompasses methods of treating solid mass tumors by direct microinjection via a microcatheter of an anti-tumor immunotherapeutic agent into the microvasculature leading into tumor thereby providing high levels of contact with the tumor while minimizing the degree of systemic buildup of the immunotherapeutic agent.